QRX-3 for Chronic Kidney Disease

(NAD agent Trial)

Age: 18+

Sex: Any

Trial Phase: Phase 2 & 3

Sponsor: Ebima Clifford Okundaye

Disqualifiers: Rapid decline, Symptomatic failure, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 1 year

2400 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What is the purpose of this trial?

Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study we are using a novel drug to target improved function of the kidneys.

Eligibility Criteria

This trial is for individuals with chronic kidney disease (CKD) who have shown a slow decline in kidney function over the past year, specifically less than a 20% drop in eGFR. Participants must have an eGFR under 60ml/min and no signs of rapid kidney failure or acute conditions superimposed on their CKD.

Inclusion Criteria

Negative Serology markers for CKD etiology

Provider perceived adherence to study follow up

Rate of decline of eGFR over the last one year of less than 20%

Exclusion Criteria

My kidney function has dropped more than 20% in the last year.

I am experiencing symptoms of kidney failure.

I am experiencing sudden kidney failure.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive QRX-3 or placebo for the prevention and treatment of chronic kidney disease progression

1 year

Regular visits as per study protocol

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• QRX-3

Trial Overview The study tests QRX-3, a new drug aimed at improving kidney function and slowing down the progression of CKD. The goal is to see if this medication can prevent patients from reaching stages that require dialysis or lead to renal failure.

Participant Groups

Group I: intervention Active Control 1 Intervention

QRX-3 - two capsules twice daily

Group II: placebo Placebo Group 1 Intervention

placebo pill - one pill twice daily

Who Is Running the Clinical Trial?

Ebima Clifford Okundaye

Lead Sponsor

Trials

1

Recruited

2,400+